Key takeaways from the Draft Pharma Policy 2017 & How does it impact you?

The key aims for the Draft Pharma Policy 2017 include the following key features:

  • Making essential drugs affordable for the common man
  • Ensuring quality drugs manufacturing and consumption along with exports
  • Creating an environment for R&D to produce innovative drugs
  • Providing a long term stable policy for pharmaceutical sector
  • Making Indian self sufficient when it comes to end to end indigenous drug manufacturing

We focus on the key points we feel relevant to Doctors and the general public:

Policy on Generic Drugs

The policy aims to encourage innovation in drugs along with generic drugs. However, the policy states that providing branded names to generic drugs will be discouraged as it hampers innovation.

Therefore, the policy states to promote single ingredient drugs by the salt names. However, the manufacturer of drugs can stamp over the package that contains the generic drug. Additionally, for Fixed Dosed Combinations drugs the branded names can be used.

The policy states that it would implement 1 drug, 1 company, 1 brand name, and 1 price.

Policy on Medical Practioners

The policy aims to push e-prescriptions into the marketplace in which Medical Practioners would only prescribe salt (generic) names through a drop down list using medical software.

The policy intends to promote e-pharmacy and will create opportunities to increase investment and opportunities in the same space.

Policy on Trade Margins

The policy has stated that Stockist, Distributors, and Retailers have adversely affected consumer interest. Therefore, a level of trade margins will be set to bring down prices. Moreover, the policy of trade margins would apply even to institutions receiving drugs directly from the manufacturer.

Policy on Drug Pricing

The policy aims to control drug pricing to make it more poor oriented while retaining at the same time its industry friendliness. National List of Essential medicines will remain for medicines to be under price regulation. The prices would be regulated by the National Pharmaceutical Pricing Authority.